益生菌制剂治疗非酒精性脂肪性肝炎的疗效：一项试验性试

StephenW

Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial

    Elina Manzhalii1, Oleksandr Virchenko2, Tetyana Falalyeyeva2, Tetyana Beregova2 andWolfgang Stremmel3,*

DOI: 10.1111/1751-2980.12561

This article is protected by copyright. All rights reserved.


Vol. 18 Issue 9
Journal of Digestive Diseases

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)
Article has an altmetric score of 8

    1    Department of Internal Medicine of Propedeutics No. 2, Bogomolets National Medical University and Diagnostic Center of Podil Community, Kiev, Ukraine
    2    Institute of Biology and Medicine, Taras Shevchenko National University, Kiev, Ukraine
    3    Department of Internal Medicine (Gastroenterology), University Clinics of Heidelberg, Heidelberg, Germany

Email: Wolfgang Stremmel ([email protected])

**Correspondence to: Wolfgang Stremmel, University Clinics of Heidelberg, 69120 Heidelberg, Germany. E-mail: [email protected]; telephone: +49-6221-568700; Fax: +49-6221-564116 (on behalf of Elina Manzhalii)

Keywords:

    clinical trial;inflammation;low-fat/low-calorie diet;probiotic;non-alcoholic steatohepatitis (NASH)

Abstract
AIM

To evaluate the therapeutic effect of a probiotic cocktail containing lactobacilli, bifidobacteria, and Streptococcus thermophilus on non-alcoholic steatohepatitis (NASH).
METHODS

In this open-label trial, 75 patients with NASH fed a low-fat/low-calorie diet were randomly divided into the control group (n = 37) and the experimental group (n = 38) also receiving the probiotic cocktail once daily for 12 weeks.
RESULTS

All patients were diagnosed with fatty liver by ultrasound examination and had elevated levels of gamma-glutamyl transferase (GGT) and alanine aminotransferase (ALT), and slightly increased body mass index (BMI) and cholesterol levels. BMI and serum cholesterol were reduced by the low-fat/low-calorie diet, but ALT was not. However, the short-term (12-week) treatment with the probiotic cocktail caused a significant (by >20%) reduction of serum ALT compared to control, indicating improvement of the inflammation state. Accordingly, liver stiffness was decreased in the probiotic-treated group compared to the control group (P < 0.05). Moreover, a more significant decrease in the BMI and serum cholesterol was observed in the probiotic-treated group compared to control (P < 0.05). However, the reduction of GGT as a steatosis marker was insignificant. The composition of stool microbiota in probiotic-treated patients demonstrated a shift towards a normal pattern for all examined bacterial species. No adverse events were observed in any patient during the trial.
CONCLUSION

Short-term treatment with the probiotic cocktail caused significant improvement of liver inflammation status without adverse events and, thus, may represent a promising candidate therapeutic approach for NASH.

StephenW

益生菌制剂治疗非酒精性脂肪性肝炎的疗效：一项试验性试验

    Elina Manzhalii1，Oleksandr Virchenko2，Tetyana Falalyeyeva2，Tetyana Beregova2和Wolfgang Stremmel3，*

DOI：10.1111 / 1751-2980.12561

本文受版权保护。版权所有。


卷。 18期9
消化系统疾病杂志

接受的文章（接受，未经编辑的文章在线发表，可引用，未来将出现最终的编辑和排版版本）。
文章有一个8位的比较评分

    1 Bogomolets国立医学大学Propedeutics 2号内科和乌克兰基辅Podil社区诊断中心
    2乌克兰基辅塔拉斯舍甫琴科国立大学生物医学研究所
    3德国海德堡海德堡大学医学院内科（消化内科）

电子邮件：Wolfgang Stremmel（[email protected]）

**通讯作者：Wolfgang Stremmel，海德堡大学诊所，6912​​0德国海德堡。电子邮件：[email protected];电话：+ 49-6221-568700;传真：+ 49-6221-564116（代表Elina Manzhalii）

关键词：

    临床试验;炎症;低脂肪/低热量饮食;益生菌;非酒精性脂肪性肝炎（NASH）

抽象
目标

评估含有乳杆菌，双歧杆菌和嗜热链球菌的益生菌混合物对非酒精性脂肪性肝炎（NASH）的治疗效果。
方法

在这个开放标签试验中，75名NASH低脂低热量饮食患者随机分为对照组（n = 37）和实验组（n = 38），每天一次接受益生菌鸡尾酒12周。
结果

所有患者均通过超声检查确诊为脂肪肝，并且具有高水平的γ-谷氨酰转移酶（GGT）和丙氨酸转氨酶（ALT），并且体重指数（BMI）和胆固醇水平稍微升高。 BMI和血清胆固醇被低脂肪/低热量饮食降低，但ALT不是。然而，与对照相比，益生菌混合物的短期（12周）治疗引起血清ALT的显着（> 20％）降低，表明炎症状态的改善。因此，益生菌处理组的肝硬度与对照组相比降低（P <0.05）。此外，与对照相比，在益生菌处理组中观察到BMI和血清胆固醇显着降低（P <0.05）。然而，GGT作为脂肪变性标志物的减少不明显。益生菌治疗患者的粪便微生物群的组成表现出对所有检查的细菌物种的正常模式的转变。在试验期间没有观察到任何患者的不良事件。
结论

益生菌混合物的短期治疗导致肝脏炎症状态的显着改善而没有不良事件，因此可能代表NASH的有希望的候选治疗方法。

Espoir

益生菌混合物的短期治疗导致肝脏炎症状态的显着改善而没有不良事件，因此可能代表NASH的有希望的候选治疗方法。
——看来益生菌对非酒精性脂肪性肝炎的还是很不错的